Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Novartis preps Zykadia for a frontline NSCLC pitch, but faces a tough rival in Roche; J&J, GSK hustle RA drug sirukumab to the FDA
Novartis preps Zykadia for a frontline NSCLC pitch, but faces a tough rival in Roche; J&J, GSK hustle RA drug sirukumab to the FDA
Novartis preps Zykadia for a frontline NSCLC pitch, but faces a tough rival in Roche; J&J, GSK hustle RA drug sirukumab to the FDA
Submitted by
admin
on September 23, 2016 - 11:47am
Source:
Endpoints
News Tags:
Novartis
Zykadia
non-small cell lung cancer
Roche
JNJ
GSK
rheumatoid arthritis
sirukumab
Headline:
Novartis preps Zykadia for a frontline NSCLC pitch, but faces a tough rival in Roche; J&J, GSK hustle RA drug sirukumab to the FDA
Do Not Allow Advertisers to Use My Personal information
